(Q34303205)

English

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

cancer diagnosis

1 reference

based on heuristic

inferred from title

5

object named as

H B Muss

1 reference

Europe PubMed Central

1 August 2017

2

object named as

J N Ingle

1 reference

Europe PubMed Central

1 August 2017

author name string

P E Goss

1

1 reference

Europe PubMed Central

1 August 2017

S Martino

3

1 reference

Europe PubMed Central

1 August 2017

N J Robert

4

1 reference

Europe PubMed Central

1 August 2017

R B Livingston

6

1 reference

Europe PubMed Central

1 August 2017

N E Davidson

7

1 reference

Europe PubMed Central

1 August 2017

E A Perez

8

1 reference

Europe PubMed Central

1 August 2017

Y Chavarri-Guerra

9

1 reference

Europe PubMed Central

1 August 2017

D A Cameron

10

1 reference

Europe PubMed Central

1 August 2017

K I Pritchard

11

1 reference

Europe PubMed Central

1 August 2017

T Whelan

12

1 reference

Europe PubMed Central

1 August 2017

L E Shepherd

13

1 reference

Europe PubMed Central

1 August 2017

D Tu

14

1 reference

Europe PubMed Central

1 August 2017

publication date

1 October 2012

1 reference

Europe PubMed Central

1 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

1 August 2017

24

1 reference

Europe PubMed Central

1 August 2017

2

1 reference

Europe PubMed Central

1 August 2017

355-361

1 reference

Europe PubMed Central

1 August 2017

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Adjuvant endocrine therapy for premenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Aromatase inhibitors for female infertility: a systematic review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Breast cancer. Clinical practice guidelines in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Summary of aromatase inhibitor trials: the past and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551482

6 July 2018

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS330

21 January 2018

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23028039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDS330

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34303205&oldid=1966738052"